Cleveland Clinic Laboratories Technical Update • October 2011 Cleveland Clinic Laboratories is dedicated to keeping you updated and informed about recent testing changes. That's why we are happy to provide this technical update on a monthly basis. Recently changed tests are bolded, and could include revisions to methodology, reference range, days performed or CPT code. For your convenience, tests are listed alphabetically and the order and billing codes are provided. If you wish to compare the new information with previous test demographics, refer to the Test Directory, which can be accessed at clevelandcliniclabs.com. Deleted tests and new tests are listed separately. Please update your database as necessary. For additional detail, contact Client Services at 216.444.5755 or 800.628.6816 or via email at
[email protected].
Da ys
Sp
r Pe st
Co
T
d
te
CP
or
y
ge
an
eR
ge
log
do
ep /R
ed
m
for
nc
re
fe Re
an
t
en
em
ion
at
Ch
ho
et
M
nt
ne
uir
d
ue
t
s Te
tin
m
for
In
q Re
po
m
en
im
Co
ec
ial
ec on
Cannabinoid Confirmation, Urine
isc
Canavan Disease Mutation, Whole Blood
8
tD
8
e
Canavan Disease Mutation, Fluid
w
8
ng
Benzodiazepines Confirmation, Urine Calpain 3 DNA Sequencing Test
Ne
8 3
Sp
s Te
Bartonella PCR, Tissue
e
8
ha
Autosomal Dominant Ataxia Evaluation
od
Autoimmune Polyglandular Syndrome
8
eC
3, 8
m
Amoxapine and Metabolite
Na
Allergen, Mushroom IgE
8
e
Allergen, Flounder IgE
7
gC
7
od
Allergen, Cocklebur IgE
Chromium, Blood
9
CMT Evaluation, Complete
9
CMT Evaluation, Partial
9
Cocaine Confirmation, Urine
3, 9
Complete HNPP Evaluation
3
Connexin 26
9
Copper
9
Copper/Zinc
9
Date Rape Panel
3
Drug Analysis, Comprehensive
3, 9
lin
Admark PS-1 Analysis, Symptomatic
7
rC
8
10
Bi
de
Or
e at pd # t U age P
s Te
Summary of Changes by Test Name
Duchenne/Becker Muscular Dystrophy DNA Carrier (females only)
9500 Euclid Avenue | Cleveland, Ohio 44195 | 216.444.5755 | 800.628.6816 | clevelandcliniclabs.com 1
3
Early Onset Obesity Evaluation
4
FALS Disease DNA Test Fentanyl
9
Flunitrazepam Screen, Urine
4
Flunitrazepam, Serum
4
FTA Antibodies, CSF
4
Gabitril
4, 9
Gamma-Hydroxybutyric Acid, Serum
9
Gamma-Hydroxybutyric Acid, Urine
9
Gaucher Disease Mutation, Fluid
9
Gaucher Disease Mutation, Whole Blood
4
GCK (CH) DNA Sequencing Test
4
GCK (NDM) DNA Sequencing Test
4
Heavy Metal Screen with Cadmium, Random Urine
4
Heparin Anti Xa Assay
4
Hepatitis Be Antigen
9
Hereditary Spastic Paraplegia
10
Inhibin B
4
Insulin Like Growth Factor Binding Protein 2
4
Ipecac Biomarkers
4, 9 4, 9
IPF1 (MODY4) DNA Sequencing Test IPF1 (NDM) DNA Sequencing Test
4
KCNJ11 (CH) DNA Sequencing Test
4
KCNJ11 (NDM) DNA Sequencing Test
11 9 4, 9 4 10 9 10
Lead and ZPP OSHA Panel Lead, Blood Limb Girdle Muscular Dystrophy Evaluation LMW Anti Xa Assay Manganese, Blood Maprotiline MDMA, Blood
4
Mercaptopurine
4
MERRF mtDNA Evaluation
10 4 10 4, 10 10 5, 10 10 5 5, 10
e Fe
Dystrophin
4, 9
T CP
Duchenne/Becker Muscular Dystrophy DNA Deletion (Males only)
3
5
d te or ep /R ge ed an rm rfo eR Pe nc y re ys log efe Da do R ho et ge M an Ch nt t ne en m po re m i Co qu Re ion at en m im or f ec In ed Sp ial inu ec nt o Sp sc st Di Te st ew Te N e ng ha eC e m od Na gC lin Bi de Co
3, 9
er
e at pd # t U age P
d Or
s Te
Summary of Changes by Test Name
Methadone MFN2 DNA Sequencing Test MODY3 (TCF1) DNA Sequencing MODY5 (TCF2) DNA Sequencing Test Mycobacterium tuberculosis Complex PCR, Tissue Myelin Protein Zero DNA Sequencing Test Myeloperoxidase Autoantibodies NAbFeron Antibody Neopterin Neurofibromatosis Type 2 DNA
9500 Euclid Avenue | Cleveland, Ohio 44195 | 216.444.5755 | 800.628.6816 | clevelandcliniclabs.com
2
d te or ep /R ge ed an rm rfo eR Pe nc y re ys log efe Da do R ho et ge M an Ch nt t ne en m po re m i Co qu Re ion at en m im or f ec In ed Sp ial inu ec nt o Sp sc st Di Te st ew Te N e ng ha eC e m od Na gC lin Bi de Co
er
Neutrophil Cytoplasmic Antibody
10
Niemann-Pick Disease Type A Mutation, Fluid
10
Niemann-Pick Disease Type A Mutation, Whole Blood
7
OSHA Zinc Protoporphyrin
8
Parenteral Nutrition Package
8, 10
Phencyclidine Confirmation, Urine
5
PINK1 DNA Sequencing
5
PMP22 DNA Sequencing Test
5, 10 8
PMP22 Duplication/Deletion DNA Pneumococcal IgG Antibodies
5, 10
Post DDAVP Monitoring
6, 10
Pre DDAVP Monitoring
10
Pregabalin
10
Quetiapine
6
Ritalin
6
Rubella IgG Antibody
6
SCA14 DNA Test
6, 10
SETX DNA Sequencing
11
Streptococcal Pneumo. Antibodies
6
Sulfonylurea Hypoglycemics, Urine
10 6
e Fe
5, 10
T CP
e at pd # t U age P
d Or
s Te
Summary of Changes by Test Name
Thioridazine Vancomycin, Pre Dose
10
Warfarin
10
Zinc
Test Changes Test Name
Order Code
Billing Code
Change
Effective Date
Autoimmune Polyglandular Syndrome
AIRE
83293
CPT: 83891, 83898x14, 83904x14, 83909x14
10/13/2011
Calpain 3 DNA Sequencing Test
CALP3
83055
CPT: 83891, 83898x22, 83904x22, 83909x22
10/6/2011
Complete HNPP Evaluation
HNPP
82120
CPT: 83891, 83894x4, 83900, 83901x31, 83909x5, 83914x33, 83904x4
10/13/2011
Connexin 26
CON26
81933
CPT: 83891, 83898x3, 83904x3, 83909x3
10/13/2011
Drug Analysis, Comprehensive
DRANCO
82053
CPT: 82055x2, 80101x20, 82541x2
11/3/2011
Duchenne/Becker Muscular Dystrophy DNA Carrier (females only)
DBMDXS
83006
CPT: 83891, 83900, 83901x23, 83909x2, 83914x95
10/13/2011
Duchenne/Becker Muscular Dystrophy DNA Deletion (Males only)
DBMDYS
82119
CPT: 83891, 83900, 83901x93, 83909x2, 83914x95
10/13/2011
Dystrophin
DYSTRO
76163
CPT: 88372-59 x2
10/6/2011
Early Onset Obesity Evaluation
OBESTY
83295
CPT: 83891, 83898x3, 83909x3, 83904x3
10/13/2011
9500 Euclid Avenue | Cleveland, Ohio 44195 | 216.444.5755 | 800.628.6816 | clevelandcliniclabs.com
3
Test Changes (cont.) Test Name
Order Code
Billing Code
Change
Effective Date
FALS Disease DNA Test
FALS
82343
CPT: 83891, 83898x5, 83909x5, 83904x5
10/13/2011
Fentanyl
FENYL
75465
CPT: 83925
10/3/2011
Flunitrazepam, Serum
FLUNS
82106
CPT: 80154
10/3/2011
FTA Antibodies, CSF
FTACSF
79231
Days Performed: Sunday - Saturday
9/12/2011
Reported: 2 - 5 days Gabitril
GABIT
80319
CPT: 82542
10/3/2011
Gamma-Hydroxybutyric Acid, Serum
GHBSER
82415
Specimen Requirement: 5 mL serum from a red top tube, Refrigerated
10/13/2011
GCK (CH) DNA Sequencing Test
GCKCH
83323
CPT: 83891, 83898x9, 83909x9, 83904x9
10/13/2011
GCK (NDM) DNA Sequencing Test
GCKNDM
83328
CPT: 83891, 83898x9, 83909x9, 83904x9
10/13/2011
Heavy Metal Screen with Cadmium, Random Urine
UTXMCR
81520
CPT: 82175, 82300, 83655, 83825, 82570
10/3/2011
Heparin Anti Xa Assay
HEPASY
26114
Test Name: Previously Heparin fXa Inhibition
10/10/2011
Hepatitis Be Antigen
HBEAG
86290
Specimen Requirement: 1 mL serum from a serum separator tube, Remove serum from cells within 2 hours of collection; Refrigerated
9/16/2011
CPT: 82491
Days Performed: Sunday - Saturday Reported: 2 - 3 days Insulin Like Growth Factor Binding Protein 2
IGFBP2
79461
Specimen Requirement: 1 mL serum from a serum separator tube, Frozen; Fasting is preferred
10/17/2011
Reference Range: (ng/mL) 5 - 9.9 years: 49 - 208 10 - 13.9 years: 41 - 167 14 - 17.9 years: 37 - 135 18 - 49 years: 38 - 267 >49 years: 47 - 350 Days Performed: Wednesday Reported: 3 - 5 days
Ipecac Biomarkers
IPECAC
87789
Reference Range: Emetine: < 75 ng/mL Cephaeline: Not established
10/13/2011
Days Performed: Varies Reported: 5 - 7 days IPF1 (MODY4) DNA Sequencing Test
MODY4
83310
CPT: 83891, 83898x4, 83909x4, 83904x4
10/13/2011
IPF1 (NDM) DNA Sequencing Test
IPFNDM
83325
CPT: 83891, 83898x4, 83909x4, 83904x4
10/13/2011
KCNJ11 (CH) DNA Sequencing Test
KCNJCH
83357
CPT: 83891, 83898x4, 83904x4, 83909x4
10/6/2011
KCNJ11 (NDM) DNA Sequencing Test
KCNJ
83327
CPT: 83891, 83898x4, 83904x4, 83909x4
10/6/2011
Limb Girdle Muscular Dystrophy Evaluation
LGRDL
82958
CPT: 83891, 83898x103, 83904x103, 83909x103
10/13/2011
LMW Anti Xa Assay
LMWHEP
81281
Test Name: Previously Low Molecular Weight Heparin Assay
10/10/2011
Mercaptopurine
MERCAP
83754
CPT: 82491
10/13/2011
MERRF mtDNA Evaluation
MERRF
82400
CPT: 83891, 83892x4, 83898x4, 83909x4
10/6/2011
MFN2 DNA Sequencing Test
MFN2
83400
CPT: 83891, 83898x15, 83904x15, 83909x15
10/6/2011
MODY5 (TCF2) DNA Sequencing Test
MODY5
83311
Specimen Requirement: 10 mL whole blood in an ACD A or B yellow top tube; Collect Monday - Wednesday only; Send to Cleveland Clinic Laboratories on the day of collection, Ambient
10/6/2011
CPT: 83891, 83898x9, 83904x9, 83909x9
9500 Euclid Avenue | Cleveland, Ohio 44195 | 216.444.5755 | 800.628.6816 | clevelandcliniclabs.com
4
Test Changes (cont.) Test Name
Order Code
Billing Code
Change
Effective Date
Myelin Protein Zero DNA Sequencing Test
MPZERO
82186
CPT: 83891, 83898x6, 83904x6, 83909x6
10/6/2011
NAbFeron Antibody
NABFAB
81430
CPT: 86382, 87253
10/13/2011
Neopterin
NEOPT
81723
Specimen Requirement: 2 mL serum from a serum separator tube; Protect from light; Patient should fast for 12 hours prior to collection; Remove serum from cells within 2 hours of collection; Frozen
10/6/2011
Reference Range: 4.0 - 16.8 nmol/L Days Performed: Tuesday Reported: 2 - 9 days Neurofibromatosis Type 2 DNA
NEUFIB
82303
CPT: 83891, 83898x18, 83903x18, 83904x18, 83909x18
10/6/2011
Neutrophil Cytoplasmic Antibody
ANCA
76168
Components: C-ANCA and P-ANCA by Indirect Immunofluorescence Assay (IFA); If either is positive, Protease 3 Autoantibodies (C-ANCA) by EIA and/or Myeloperoxidase Autoantibodies (P-ANCA) by EIA will be performed at an additional charge.
10/12/2011
Methodology: Indirect Fluorescent Antibody (IFA) Days Performed: Monday - Friday Reported: 1 - 5 days CPT: 86255x2 Specimen Requirement: 10 mL whole blood in an EDTA lavender top tube; Collect Monday - Wednesday only; Send to Cleveland Clinic Laboratories on the day of collection; Ambient
PINK1 DNA Sequencing
PINK1
83049
10/6/2011
PMP22 DNA Sequencing Test
PMP22
82201
CPT: 83891, 83898x4, 83904x4, 83909x4
10/6/2011
PMP22 Duplication/ Deletion DNA
PMPDEL
82200
CPT: 83891, 83900, 83901x31, 83909, 83914x33
10/13/2011
Post DDAVP Monitoring
DDAPOS
82266
Special Information: This order should be placed on a sample drawn one hour after DDAVP administration. Note: 3.2% sodium citrate is the preferred anticoagulant recommended by CLSI.
10/11/2011
CPT: 83891, 83898x8, 83904x8, 83909x8
Components: von Willebrand Factor Antigen Ristocetin Co-Factor Factor VIII Assay Collagen Binding Assay Methodology: Aggregation, Latex Immunoassay (LIA), Clotting Assay, Enzyme-Linked Immunosorbent Assay (ELISA) Reference Range: von Willebrand Factor Antigen: 0-2 days: 36 - 315 % 2 - 6 days: 50 - 279 % 6 - 30 days: 19 - 270 % 1 - 4 months: 57 - 226 % 4 - 12 months: 23 - 216 % 1 - 6 years: 60 - 132 % 6 - 11 years: 44 - 158 % 11 - 17 years: 46 - 168 % 17 - 99 years: 50 - 173 % Ristocetin Co-Factor: 35 - 153 % Factor VIII Assay: 0 - 1 days: 22 - 207 % 2 - 5 days: 22 - 179 % 6 - 30 days: 25 - 183 % 1 - 3 months: 33 - 148 % 4 - 11 months: 37 - 127 % 1 - 99 years: 50 - 173 % Collagen Binding Assay: 41 - 161 % CPT: 85246, 85245, 85240, 83520, 85390
9500 Euclid Avenue | Cleveland, Ohio 44195 | 216.444.5755 | 800.628.6816 | clevelandcliniclabs.com
5
Test Changes (cont.) Test Name
Order Code
Billing Code
Change
Effective Date
Pre DDAVP Monitoring
DDAPRE
82267
Special Information: This order should be placed on a sample drawn before DDAVP administration to establish a baseline. Note: 3.2% sodium citrate is the preferred anticoagulant recommended by CLSI.
10/11/2011
Components: von Willebrand Factor Antigen Ristocetin Co-Factor Factor VIII Assay Collagen Binding Assay Methodology: Aggregation, Latex Immunoassay (LIA), Clotting Assay, Enzyme-Linked Immunosorbent Assay (ELISA) Reference Range: von Willebrand Factor Antigen: 0-2 days: 36 - 315 % 2 - 6 days: 50 - 279 % 6 - 30 days: 19 - 270 % 1 - 4 months: 57 - 226 % 4 - 12 months: 23 - 216 % 1 - 6 years: 60 - 132 % 6 - 11 years: 44 - 158 % 11 - 17 years: 46 - 168 % 17 - 99 years: 50 - 173 % Ristocetin Co-Factor: 35 - 153 % Factor VIII Assay: 0 - 1 days: 22 - 207 % 2 - 5 days: 22 - 179 % 6 - 30 days: 25 - 183 % 1 - 3 months: 33 - 148 % 4 - 11 months: 37 - 127 % 1 - 99 years: 50 - 173 % Collagen Binding Assay: 41 - 161 % CPT: 85246, 85245, 85240, 83520, 85390 Ritalin
RITAL
77096
CPT: 82542
10/3/2011
Rubella IgG Antibody
RUBQNT
50129
Reference Range: Negative:
